Want to see HK:2137 full AI Analyst Report?
2137 Stock Chart & Stats
HK$1.44
HK$0.04(3.74%)
At close: 4:00 PM EST
HK$1.44
HK$0.04(3.74%)
Day’s Range― - ―
52-Week RangeHK$0.82 - HK$1.90
Previous CloseN/A
Volume2.92M
Average Volume (3M)477.49K
Market Cap
HK$672.14M
Enterprise Value-HK$1.40B
Total Cash (Recent Filing)HK$1.77B
Total Debt (Recent Filing)HK$6.18M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding735,453,300
10 Day Avg. Volume563,825
30 Day Avg. Volume477,491
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive Equity CushionVery low leverage reduces financial risk and preserves flexibility compared with a highly indebted biotechnology model. Positive equity through 2025 provides a capital cushion that can support ongoing development and commercialization activities, although losses continue to consume resources.
Reduced Loss And Cash Burn In 2025The smaller 2025 loss and reduced cash outflow indicate some operational improvement after the severe 2024 performance. If maintained, this could extend financial resources and improve the company’s ability to fund development and commercialization while pursuing a path toward stronger economics.
Partnered And In-licensed Business ModelA partnered and in-licensed model gives Brii access to external drug candidates, development expertise, and commercialization capabilities without relying entirely on internally originated assets. Collaborations can also provide milestone, royalty, and cost-sharing opportunities as products advance.
Bears Say
Persistent Losses And Deeply Negative MarginsPersistent losses and deeply negative margins show that the current business has not yet reached sustainable profitability. This weak earnings base can constrain reinvestment, reduce resilience during development setbacks, and leave future financial performance dependent on successful product execution.
Ongoing Negative Operating And Free Cash FlowConsistently negative operating and free cash flow means the company is not currently funding its activities from internally generated cash. Continued cash burn increases reliance on existing liquidity or external funding and can limit the pace and flexibility of future development investments.
Sharp 2025 Revenue ContractionA sharp revenue decline weakens evidence of commercial scale and product momentum, particularly for a company that depends on marketed and partnered therapies. Sustained contraction could reduce operating leverage, delay the route to profitability, and make future revenue less predictable.
Brii Biosciences Limited News
2137 FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was HK$0.81 and its highest was HK$1.90 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is HK$672.14M.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Mar 19, 2027 which is in 141 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Aug 20, 2026. The company reported -HK$0.164 earnings per share for the quarter, missing the consensus estimate of -HK$0.129 by -HK$0.035.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 735,453,300 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -HK$0.164 in its last earnings report, missing expectations of -HK$0.129. Following the earnings report the stock price went up 3.571%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in HK:2137
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brii Biosciences Limited
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Technical Analysis
Mabpharm Limited
―
Clover Biopharmaceuticals Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Transcenta Holding Limited
―
AIM Vaccine Co., Ltd. Class H
―